{
    "clinical_study": {
        "@rank": "119228", 
        "arm_group": [
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive radiotherapy alone as in arm 1."
            }, 
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area."
            }
        ], 
        "brief_summary": {
            "textblock": "This phase III study is designed to examine if low-risk (lymph node negative), stage I a2-II\n      b cervical cancer patients treated by paclitaxel/cisplatin chemoradiation have greater\n      toxicities but similar survival rate as those treated by radiotherapy alone."
        }, 
        "brief_title": "Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Cervical carcinoma is one of the most common gynecologic cancers worldwide. Concurrent\n      radiotherapy with cisplatin-based chemotherapy has become the standard treatment for\n      patients with high risk factors cervical cancer. However, the treatment modality in patients\n      with low-risk (lymph node negative) is still disputable. It is not yet known whether\n      cisplatin-based chemoradiotherapy are more effective than radiotherapy alone in treating\n      these patients.\n\n      Therefore, the investigators are going to perform the efficacy and safety study of\n      postoperative concurrent paclitaxel/cisplatin chemoradiotherapy vs. radiotherapy alone in\n      lymph node negative patients with early-stage cervical cancer following radical\n      hysterectomy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Undertaken radical hysterectomy with diagnosis of invasive cervical cancer\n             (non-small cell type)\n\n          -  Negative lymph node\n\n          -  At least two risk factors (interstitial infiltration of greater than 1/3, vascular or\n             lymphatic involvement, cervix neoplasms larger than 4 cm, nerve involvement)\n\n          -  Eastern Cooperative Oncology Group 0-2\n\n          -  Expected life span over 6 months.\n\n          -  No distant metastasis\n\n          -  Adequate bone marrow functions (absolute neutrophil count\u2265 1,500/ul, blood platelet\u2265\n             100,000/ul, haemoglobin\u2265 10g/dl)\n\n          -  Adequate renal functions(serum creatinine \u2264 1.5mg/dl)\n\n          -  Adequate liver functions (serum bilirubin \u2264 1.5mg/dl, aspartate\n             aminotransferase/alanine aminotransferase \u2264 3 times(normal value)\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Previous history of chemotherapy or radiation\n\n          -  Hypersensitive reaction to platinum/paclitaxel agent\n\n          -  History of other cancer\n\n          -  Concurrent systemic illness not appropriate for chemotherapy\n\n          -  Active infection requiring antibiotics\n\n          -  Pregnancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756170", 
            "org_study_id": "WZMC-11352"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 2", 
                    "Arm 1"
                ], 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cervical cancer", 
            "radiotherapy", 
            "postoperative therapy", 
            "chemotherapy"
        ], 
        "lastchanged_date": "December 19, 2012", 
        "location": {
            "contact": {
                "email": "wzxiecongying@163.com", 
                "last_name": "congying xie, MD", 
                "phone": "+86-577-88069316"
            }, 
            "facility": {
                "address": {
                    "city": "Wenzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "325000"
                }, 
                "name": "The First Affiliated Hospital of Wenzhou Medical College"
            }, 
            "investigator": {
                "last_name": "congying xie, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy", 
        "other_outcome": {
            "description": "assessed by NCI Common Terminology Criteria v3.0", 
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "wzxiecongying@163.com", 
            "last_name": "congying xie, MD", 
            "phone": "+86-577-88069316"
        }, 
        "overall_official": {
            "affiliation": "the 1st Affiliated Hospital of Wenzhou Medical College", 
            "last_name": "Congying Xie, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756170"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wenzhou Medical College", 
            "investigator_full_name": "xie congying", 
            "investigator_title": "Director", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Wenzhou Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "xie congying", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}